학술논문

Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population‐based study
Document Type
article
Source
Cancer. 127(24)
Subject
Biomedical and Clinical Sciences
Cardiovascular Medicine and Haematology
Oncology and Carcinogenesis
Cancer
Rare Diseases
Lymphoma
Hematology
Pediatric Cancer
Pediatric
Clinical Research
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
Black People
Bleomycin
Child
Doxorubicin
Ethnicity
Hispanic or Latino
Hodgkin Disease
Humans
Vinblastine
Young Adult
adolescent
adolescent and young adult
disparities
Hodgkin lymphoma
outcomes
pediatric
registry
Public Health and Health Services
Oncology & Carcinogenesis
Oncology and carcinogenesis
Public health
Language
Abstract
BackgroundHodgkin lymphoma (HL) is a treatable tumor affecting children, adolescents and young adults (AYAs; 15-39 years old). Population-based studies report worse survival for non-White children and AYAs but have limited data on individual therapeutic exposures. This study examined overall and HL-specific survival in a population-based cohort of patients while adjusting for sociodemographic factors and treatment.MethodsData for 4807 patients younger than 40 years with HL (2007-2017) were obtained from the California Cancer Registry. Individual treatment information was extracted from text fields; chemotherapy regimens were defined by standard approaches for pediatric and adult HL. Multivariable Cox models examined the influence of patient and treatment factors on survival.ResultsAt a median follow-up of 4.4 years, 95% of the patients were alive. Chemotherapy differed by age, with 70% of 22- to 39-year-olds and 41% of